Jamil Beg

Director at AdvanCell.

Raised on AdvanCell filings

$218.3M

of $315M offered across 1 Form D filing

Form D filings: 1
Teammates: 10
Last filing: Jul 16, 2026

Company

Biotech · Cambridge, MA

Lead-212 alpha therapies for prostate and other cancers

Lead-212 alpha therapies for prostate and other cancers

Investors: 41
Founded: 2026
Still open: $96.7M

Investors: 41
Sector: Biotech
Founded: 2026
HQ: Cambridge, MA

AdvanCell filings

AdvanCell Form D filings
Filed	Security	Sold of offered	Filing
Jul 16, 2026	Equity	$218.3M/ $315M	Form D

EquityFiled Jul 16, 2026Form D
$218.3M/ $315M

Works with

Also named on AdvanCell filings

Aaron PickettSecretary, Form D signerForm D signer Anthony AiudiDirector Kevin CameronDirector Wing Cheong LamDirector Andrew AdamovichDirector Andrew KayDirector Bali MuralidharDirector Christopher GagliardiDirector Nik EconomopoulosDirector Philina LeeExecutive Officer, Director